Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Files for $750M Notes Offering

NEW YORK (GenomeWeb News) – Agilent Technologies has filed a prospectus with the US Securities and Exchange Commission to offer $750 million in senior notes.

The firm said that of these notes, $500 million will mature in September 2015 and will bear an annual interest rate of 5.5 percent, while $250 million will mature in September 2012 with an annual interest rate of 4.45 percent.

Agilent said that it intends to use the proceeds from the offering for general corporate purposes, which may include its acquisition of Varian, other acquisitions, capital expenditures, or repurchasing its common stock.

Agilent announced at the end of July that it would acquire Varian for around $1.5 billion. The deal is expected to expand Agilent's presence in the life sciences research and applied markets, such as the environment and energy.

The company expects to close the offering on Sept. 14, 2009.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.